Published in J Antimicrob Chemother on February 01, 2003
Combination antifungal therapy. Antimicrob Agents Chemother (2004) 3.49
Potent synergistic in vitro interaction between nonantimicrobial membrane-active compounds and itraconazole against clinical isolates of Aspergillus fumigatus resistant to itraconazole. Antimicrob Agents Chemother (2004) 0.98
Pharmacokinetic drug interaction profile of omeprazole with adverse consequences and clinical risk management. Ther Clin Risk Manag (2013) 0.96
Isolated Pancreatic Histoplasmosis: An Unusual Suspect of Pancreatic Head Mass in an Immunocompetent Host. Perm J (2015) 0.81
Important drug classes associated with potential drug-drug interactions in critically ill patients: highlights for cardiothoracic intensivists. Ann Intensive Care (2015) 0.80
Examining sex-related differences in enteric itraconazole metabolism in healthy adults using grapefruit juice. Eur J Clin Pharmacol (2008) 0.77
Pharmacokinetics and Relative Bioavailability of Orally Administered Innovator-Formulated Itraconazole Capsules and Solution in Healthy Dogs. J Vet Intern Med (2017) 0.75
Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med (1997) 5.88
Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis (2000) 3.70
Determination of itraconazole in plasma and animal tissues by high-performance liquid chromatography. J Chromatogr (1987) 2.76
Practice guidelines for the management of patients with blastomycosis. Infectious Diseases Society of America. Clin Infect Dis (2000) 2.08
Practice guideline for the treatment of coccidioidomycosis. Infectious Diseases Society of America. Clin Infect Dis (2000) 1.53
Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics. J Clin Pharm Ther (2001) 1.37
Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders. Drugs (1994) 1.29
Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Drugs (1996) 1.24
Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B. Antimicrob Agents Chemother (2000) 1.11
Effect of omeprazole on the pharmacokinetics of itraconazole. Eur J Clin Pharmacol (1998) 0.95
CYP2C19 genotypes and omeprazole metabolism after single and repeated dosing when combined with clarithromycin. Eur J Clin Pharmacol (1999) 0.83
Human dectin-1 deficiency and mucocutaneous fungal infections. N Engl J Med (2009) 5.27
Same-sex mating and the origin of the Vancouver Island Cryptococcus gattii outbreak. Nature (2005) 5.11
Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis (2006) 4.88
Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J Clin Microbiol (2004) 4.70
Sexual cycle of Cryptococcus neoformans var. grubii and virulence of congenic a and alpha isolates. Infect Immun (2003) 3.61
Combination antifungal therapy. Antimicrob Agents Chemother (2004) 3.49
The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother (2011) 3.04
Cryptococcosis. Infect Dis Clin North Am (2006) 2.82
Randomized trial of hyperthermia and radiation for superficial tumors. J Clin Oncol (2005) 2.82
Calcineurin is essential for survival during membrane stress in Candida albicans. EMBO J (2002) 2.81
An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med (2011) 2.70
Harnessing calcineurin as a novel anti-infective agent against invasive fungal infections. Nat Rev Microbiol (2007) 2.60
Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis (2008) 2.55
Hsp90 orchestrates temperature-dependent Candida albicans morphogenesis via Ras1-PKA signaling. Curr Biol (2009) 2.50
Breakthrough invasive candidiasis in patients on micafungin. J Clin Microbiol (2010) 2.47
Prospective comparison of patient experience with colon imaging tests. Am J Med (2006) 2.42
Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proc Natl Acad Sci U S A (2009) 2.35
Calcineurin controls growth, morphology, and pathogenicity in Aspergillus fumigatus. Eukaryot Cell (2006) 2.35
Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact. Clin Infect Dis (2008) 2.33
Killing of Caenorhabditis elegans by Cryptococcus neoformans as a model of yeast pathogenesis. Proc Natl Acad Sci U S A (2002) 2.29
Adenylyl cyclase functions downstream of the Galpha protein Gpa1 and controls mating and pathogenicity of Cryptococcus neoformans. Eukaryot Cell (2002) 2.21
CX3CR1-dependent renal macrophage survival promotes Candida control and host survival. J Clin Invest (2013) 2.00
Superoxide dismutase influences the virulence of Cryptococcus neoformans by affecting growth within macrophages. Infect Immun (2003) 2.00
Old drugs, new purpose: retooling existing drugs for optimized treatment of resistant tuberculosis. Clin Infect Dis (2012) 1.99
Calcineurin is essential for Candida albicans survival in serum and virulence. Eukaryot Cell (2003) 1.98
Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J (2002) 1.97
Disruption of a nonribosomal peptide synthetase in Aspergillus fumigatus eliminates gliotoxin production. Eukaryot Cell (2006) 1.92
The proactive sexual health history. Am Fam Physician (2002) 1.91
The intersection of patient complexity, prescriber continuity and acute care utilization. J Gen Intern Med (2014) 1.90
Urease expression by Cryptococcus neoformans promotes microvascular sequestration, thereby enhancing central nervous system invasion. Am J Pathol (2004) 1.87
The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328. Arch Intern Med (2007) 1.84
Comparative evaluation of Etest and sensititre yeastone panels against the Clinical and Laboratory Standards Institute M27-A2 reference broth microdilution method for testing Candida susceptibility to seven antifungal agents. J Clin Microbiol (2007) 1.78
Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis. Am J Respir Crit Care Med (2002) 1.77
Hsp90 governs echinocandin resistance in the pathogenic yeast Candida albicans via calcineurin. PLoS Pathog (2009) 1.76
Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis (2004) 1.74
When primary antifungal therapy fails. Clin Infect Dis (2008) 1.67
Identification of App1 as a regulator of phagocytosis and virulence of Cryptococcus neoformans. J Clin Invest (2003) 1.66
Immune reconstitution syndrome associated with opportunistic mycoses. Lancet Infect Dis (2007) 1.65
PKC signaling regulates drug resistance of the fungal pathogen Candida albicans via circuitry comprised of Mkc1, calcineurin, and Hsp90. PLoS Pathog (2010) 1.63
Carbonic anhydrase and CO2 sensing during Cryptococcus neoformans growth, differentiation, and virulence. Curr Biol (2005) 1.62
Outcome of lung transplantation in patients with mycetomas. Chest (2002) 1.59
A MAP kinase cascade composed of cell type specific and non-specific elements controls mating and differentiation of the fungal pathogen Cryptococcus neoformans. Mol Microbiol (2003) 1.55
Differential effects of inhibiting chitin and 1,3-{beta}-D-glucan synthesis in ras and calcineurin mutants of Aspergillus fumigatus. Antimicrob Agents Chemother (2008) 1.55
Mating-type-specific and nonspecific PAK kinases play shared and divergent roles in Cryptococcus neoformans. Eukaryot Cell (2002) 1.55
Role of PLB1 in pulmonary inflammation and cryptococcal eicosanoid production. Infect Immun (2003) 1.55
Calcineurin inhibition or mutation enhances cell wall inhibitors against Aspergillus fumigatus. Antimicrob Agents Chemother (2007) 1.54
Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis (2006) 1.54
Iatrogenic fungal meningitis: tragedy repeated. Ann Intern Med (2012) 1.54
Identification of Cryptococcus neoformans temperature-regulated genes with a genomic-DNA microarray. Eukaryot Cell (2004) 1.54
Relationship of the glyoxylate pathway to the pathogenesis of Cryptococcus neoformans. Infect Immun (2002) 1.54
Protection against cryptococcosis by using a murine gamma interferon-producing Cryptococcus neoformans strain. Infect Immun (2007) 1.52
Is it time to abandon the use of amphotericin B bladder irrigation? Clin Infect Dis (2005) 1.51
Metabolic adaptation in Cryptococcus neoformans during early murine pulmonary infection. Mol Microbiol (2008) 1.49
In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus. Antimicrob Agents Chemother (2004) 1.46
Variants in toll-like receptors 2 and 9 influence susceptibility to pulmonary tuberculosis in Caucasians, African-Americans, and West Africans. Hum Genet (2009) 1.45
Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole. Transplantation (2005) 1.45
Antifungal serum concentration monitoring: an update. J Antimicrob Chemother (2007) 1.45
Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients. Am J Health Syst Pharm (2009) 1.44
Cryptococcosis in solid organ transplant recipients: current state of the science. Clin Infect Dis (2008) 1.44
The calcineurin target, Crz1, functions in azole tolerance but is not required for virulence of Candida albicans. Infect Immun (2004) 1.44
In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection. Antimicrob Agents Chemother (2004) 1.44
Immune reconstitution syndrome and exacerbation of infections after pregnancy. Clin Infect Dis (2007) 1.43
Characterization and regulation of the trehalose synthesis pathway and its importance in the pathogenicity of Cryptococcus neoformans. Infect Immun (2006) 1.41
Cost-effectiveness of posaconazole versus fluconazole for prevention of invasive fungal infections in U.S. patients with graft-versus-host disease. Am J Health Syst Pharm (2012) 1.41
Gpr1, a putative G-protein-coupled receptor, regulates morphogenesis and hypha formation in the pathogenic fungus Candida albicans. Eukaryot Cell (2004) 1.40
Scedosporium prolificans osteomyelitis in an immunocompetent child treated with voriconazole and caspofungin, as well as locally applied polyhexamethylene biguanide. J Clin Microbiol (2003) 1.39
Calcineurin target CrzA regulates conidial germination, hyphal growth, and pathogenesis of Aspergillus fumigatus. Eukaryot Cell (2008) 1.37
First reported case of Cryptococcus gattii in the Southeastern USA: implications for travel-associated acquisition of an emerging pathogen. PLoS One (2009) 1.34
Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam. Pharmacotherapy (2014) 1.34
Cryptococcus neoformans {alpha} strains preferentially disseminate to the central nervous system during coinfection. Infect Immun (2005) 1.33
Cryptococcus gattii: an emerging fungal pathogen infecting humans and animals. Microbes Infect (2011) 1.31
Functional genomics identifies type I interferon pathway as central for host defense against Candida albicans. Nat Commun (2013) 1.31
Comparison and temporal trends of three groups with cryptococcosis: HIV-infected, solid organ transplant, and HIV-negative/non-transplant. PLoS One (2012) 1.30
Risk of fungemia due to Rhodotorula and antifungal susceptibility testing of Rhodotorula isolates. J Clin Microbiol (2003) 1.29
Caspofungin: first approved agent in a new class of antifungals. Expert Opin Pharmacother (2003) 1.29
Cryptococcus neoformans requires a functional glycolytic pathway for disease but not persistence in the host. MBio (2011) 1.29
Value of an inhalational model of invasive aspergillosis. Med Mycol (2004) 1.29
Plasminogen alleles influence susceptibility to invasive aspergillosis. PLoS Genet (2008) 1.25
The Cryptococcus neoformans catalase gene family and its role in antioxidant defense. Eukaryot Cell (2006) 1.24
Teaching old drugs new tricks: reincarnating immunosuppressants as antifungal drugs. Curr Opin Investig Drugs (2003) 1.24
Antisense repression in Cryptococcus neoformans as a laboratory tool and potential antifungal strategy. Microbiology (2002) 1.23
A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment. Am J Respir Crit Care Med (2002) 1.23
Toll-like receptor 1 polymorphisms increase susceptibility to candidemia. J Infect Dis (2012) 1.23
Survival defects of Cryptococcus neoformans mutants exposed to human cerebrospinal fluid result in attenuated virulence in an experimental model of meningitis. Infect Immun (2010) 1.22
Role of alternative oxidase gene in pathogenesis of Cryptococcus neoformans. Infect Immun (2003) 1.22
Transcriptional regulation of chitin synthases by calcineurin controls paradoxical growth of Aspergillus fumigatus in response to caspofungin. Antimicrob Agents Chemother (2010) 1.21
The trehalose synthesis pathway is an integral part of the virulence composite for Cryptococcus gattii. Infect Immun (2009) 1.21
Early treatment of candidemia in adults: a review. Med Mycol (2010) 1.21
Cryptococcus neoformans mitochondrial superoxide dismutase: an essential link between antioxidant function and high-temperature growth. Eukaryot Cell (2005) 1.20
Phylogenomic analysis of non-ribosomal peptide synthetases in the genus Aspergillus. Gene (2006) 1.19
Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. Clin Infect Dis (2007) 1.17
Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection. Am J Respir Crit Care Med (2009) 1.16
Risk factors for mortality in patients with mucormycosis. Med Mycol (2012) 1.13
The Cryptococcus neoformans transcriptome at the site of human meningitis. MBio (2014) 1.11
Nonalcoholic steatohepatitis and nonalcoholic Fatty liver disease in young women with polycystic ovary syndrome. J Clin Endocrinol Metab (2006) 1.11
Peroxisome function regulates growth on glucose in the basidiomycete fungus Cryptococcus neoformans. Eukaryot Cell (2006) 1.10
Recommendations for training and certification for pharmacists practicing, mentoring, and educating in infectious diseases pharmacotherapy. Pharmacotherapy (2009) 1.10
NOS2A, TLR4, and IFNGR1 interactions influence pulmonary tuberculosis susceptibility in African-Americans. Hum Genet (2009) 1.10